Germany

Germany

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.36 (0.31 - 0.40) 2019 Modelled IHME
0.36 (0.32 - 0.40) 2018 Modelled IHME
0.36 (0.32 - 0.40) 2017 Modelled IHME
0.37 (0.33 - 0.41) 2016 Modelled IHME
0.37 (0.33 - 0.42) 2015 Modelled IHME
0.38 (0.33 - 0.42) 2014 Modelled IHME
0.38 (0.33 - 0.43) 2013 Modelled IHME
0.38 (0.33 - 0.43) 2012 Modelled IHME
0.39 (0.34 - 0.44) 2011 Modelled IHME
0.39 (0.34 - 0.44) 2010 Modelled IHME
0.39 (0.34 - 0.45) 2009 Modelled IHME
0.4 (0.34 - 0.45) 2008 Modelled IHME
0.4 (0.35 - 0.45) 2007 Modelled IHME
0.4 (0.35 - 0.45) 2006 Modelled IHME
0.4 (0.35 - 0.45) 2005 Modelled IHME
0.41 (0.36 - 0.46) 2004 Modelled IHME
0.41 (0.36 - 0.46) 2003 Modelled IHME
0.41 (0.36 - 0.46) 2002 Modelled IHME
0.41 (0.36 - 0.47) 2001 Modelled IHME
0.41 (0.36 - 0.47) 2000 Modelled IHME
0.42 (0.37 - 0.47) 1999 Modelled IHME
0.42 (0.37 - 0.47) 1998 Modelled IHME
0.42 (0.37 - 0.47) 1997 Modelled IHME
0.42 (0.37 - 0.47) 1996 Modelled IHME
0.42 (0.37 - 0.48) 1995 Modelled IHME
0.43 (0.37 - 0.48) 1994 Modelled IHME
0.43 (0.38 - 0.48) 1993 Modelled IHME
0.43 (0.38 - 0.48) 1992 Modelled IHME
0.43 (0.38 - 0.49) 1991 Modelled IHME
0.43 (0.38 - 0.49) 1990 Modelled IHME
0.4 (0.30 - 0.50) 2016 Modelled ECDC
0.7 (0.40 - 1.10) 2002 Survey/reported Huetter ML et al, 2014
0.5 (0.40 - 0.60) 2013 Survey/reported WolfframI et al, 2015
0.67 (0.51 - 0.90) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.02 (0.01 - 0.02) 2019 Modelled IHME
0.02 (0.01 - 0.02) 2018 Modelled IHME
0.02 (0.01 - 0.02) 2017 Modelled IHME
0.02 (0.01 - 0.02) 2016 Modelled IHME
0.02 (0.01 - 0.03) 2015 Modelled IHME
0.02 (0.01 - 0.03) 2014 Modelled IHME
0.02 (0.01 - 0.03) 2013 Modelled IHME
0.02 (0.01 - 0.03) 2012 Modelled IHME
0.02 (0.01 - 0.03) 2011 Modelled IHME
0.02 (0.01 - 0.03) 2010 Modelled IHME
0.02 (0.01 - 0.03) 2009 Modelled IHME
0.02 (0.01 - 0.03) 2008 Modelled IHME
0.02 (0.02 - 0.03) 2007 Modelled IHME
0.03 (0.02 - 0.04) 2006 Modelled IHME
0.03 (0.02 - 0.04) 2005 Modelled IHME
0.03 (0.02 - 0.05) 2004 Modelled IHME
0.04 (0.03 - 0.06) 2003 Modelled IHME
0.06 (0.04 - 0.08) 2002 Modelled IHME
0.07 (0.05 - 0.09) 2001 Modelled IHME
0.08 (0.05 - 0.10) 2000 Modelled IHME
0.08 (0.06 - 0.11) 1999 Modelled IHME
0.08 (0.06 - 0.12) 1998 Modelled IHME
0.09 (0.06 - 0.12) 1997 Modelled IHME
0.09 (0.06 - 0.12) 1996 Modelled IHME
0.1 (0.06 - 0.13) 1995 Modelled IHME
0.1 (0.07 - 0.14) 1994 Modelled IHME
0.11 (0.07 - 0.16) 1993 Modelled IHME
0.12 (0.08 - 0.17) 1992 Modelled IHME
0.13 (0.09 - 0.19) 1991 Modelled IHME
0.15 (0.10 - 0.21) 1990 Modelled IHME
0.24 (0.15 - 0.37) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
9 (6 - 13) 2019 Modelled IHME
9 (6 - 13) 2018 Modelled IHME
9 (6 - 12) 2017 Modelled IHME
9 (6 - 12) 2016 Modelled IHME
9 (6 - 13) 2015 Modelled IHME
9 (6 - 13) 2014 Modelled IHME
9 (6 - 13) 2013 Modelled IHME
9 (6 - 13) 2012 Modelled IHME
9 (6 - 13) 2011 Modelled IHME
9 (6 - 13) 2010 Modelled IHME
9 (6 - 13) 2009 Modelled IHME
9 (7 - 13) 2008 Modelled IHME
10 (7 - 13) 2007 Modelled IHME
10 (7 - 14) 2006 Modelled IHME
10 (7 - 14) 2005 Modelled IHME
10 (7 - 14) 2004 Modelled IHME
10 (7 - 14) 2003 Modelled IHME
11 (7 - 15) 2002 Modelled IHME
11 (8 - 15) 2001 Modelled IHME
11 (8 - 15) 2000 Modelled IHME
11 (8 - 15) 1999 Modelled IHME
11 (8 - 15) 1998 Modelled IHME
11 (8 - 15) 1997 Modelled IHME
11 (8 - 15) 1996 Modelled IHME
11 (8 - 16) 1995 Modelled IHME
11 (8 - 16) 1994 Modelled IHME
11 (8 - 16) 1993 Modelled IHME
11 (8 - 16) 1992 Modelled IHME
11 (8 - 16) 1991 Modelled IHME
11 (8 - 16) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
87 2018 Survey/reported WHO/UNICEF
87 2017 Survey/reported WHO/UNICEF
87 2016 Survey/reported WHO/UNICEF
87 2015 Survey/reported WHO/UNICEF
87 2014 Survey/reported WHO/UNICEF
87 2013 Survey/reported WHO/UNICEF
87 2012 Survey/reported WHO/UNICEF
87 2011 Survey/reported WHO/UNICEF
88 2010 Survey/reported WHO/UNICEF
88 2009 Survey/reported WHO/UNICEF
87 2008 Survey/reported WHO/UNICEF
86 2007 Survey/reported WHO/UNICEF
87 2006 Survey/reported WHO/UNICEF
90 2005 Survey/reported WHO/UNICEF
88 2004 Survey/reported WHO/UNICEF
90 2003 Survey/reported WHO/UNICEF
87 2002 Survey/reported WHO/UNICEF
86 2001 Survey/reported WHO/UNICEF
84 2000 Survey/reported WHO/UNICEF
81 1999 Survey/reported WHO/UNICEF
81 1998 Survey/reported WHO/UNICEF
71 1997 Survey/reported WHO/UNICEF
57 1996 Survey/reported WHO/UNICEF
45 1995 Survey/reported WHO/UNICEF
32 1994 Survey/reported WHO/UNICEF
15 1993 Survey/reported WHO/UNICEF
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
54 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
Yes
OST in at least one prison
Yes

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.81 (0.66 - 1) 2019 Modelled IHME
0.81 (0.67 - 0.99) 2018 Modelled IHME
0.8 (0.66 - 0.98) 2017 Modelled IHME
0.78 (0.65 - 0.94) 2016 Modelled IHME
0.75 (0.63 - 0.89) 2015 Modelled IHME
0.75 (0.62 - 0.88) 2014 Modelled IHME
0.74 (0.62 - 0.87) 2013 Modelled IHME
0.74 (0.62 - 0.87) 2012 Modelled IHME
0.73 (0.61 - 0.87) 2011 Modelled IHME
0.73 (0.61 - 0.86) 2010 Modelled IHME
0.72 (0.60 - 0.86) 2009 Modelled IHME
0.72 (0.60 - 0.85) 2008 Modelled IHME
0.72 (0.60 - 0.85) 2007 Modelled IHME
0.71 (0.60 - 0.84) 2006 Modelled IHME
0.7 (0.59 - 0.83) 2005 Modelled IHME
0.68 (0.57 - 0.81) 2004 Modelled IHME
0.65 (0.54 - 0.77) 2003 Modelled IHME
0.61 (0.50 - 0.73) 2002 Modelled IHME
0.57 (0.47 - 0.69) 2001 Modelled IHME
0.56 (0.45 - 0.68) 2000 Modelled IHME
0.55 (0.45 - 0.68) 1999 Modelled IHME
0.55 (0.44 - 0.67) 1998 Modelled IHME
0.55 (0.44 - 0.67) 1997 Modelled IHME
0.55 (0.44 - 0.68) 1996 Modelled IHME
0.54 (0.44 - 0.68) 1995 Modelled IHME
0.55 (0.45 - 0.68) 1994 Modelled IHME
0.58 (0.47 - 0.70) 1993 Modelled IHME
0.62 (0.51 - 0.75) 1992 Modelled IHME
0.66 (0.55 - 0.81) 1991 Modelled IHME
0.71 (0.59 - 0.87) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
0.4 (0.30 - 0.50) 2016 Modelled ECDC
0.6 (0.30 - 1) 2002 Survey/reported Huetter ML et al, 2014
0.6 (0.30 - 0.90) 2014 Modelled Gower et al, 2014
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
65 (60.60 - 69.40) 2014 Modelled Degenhardt L et al, 2017

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
31 (23 - 39) 2019 Modelled IHME
30 (23 - 39) 2018 Modelled IHME
30 (23 - 38) 2017 Modelled IHME
30 (22 - 38) 2016 Modelled IHME
30 (22 - 38) 2015 Modelled IHME
30 (22 - 38) 2014 Modelled IHME
30 (22 - 38) 2013 Modelled IHME
30 (22 - 37) 2012 Modelled IHME
30 (23 - 37) 2011 Modelled IHME
30 (23 - 37) 2010 Modelled IHME
30 (23 - 38) 2009 Modelled IHME
31 (24 - 38) 2008 Modelled IHME
31 (24 - 38) 2007 Modelled IHME
32 (24 - 39) 2006 Modelled IHME
32 (24 - 39) 2005 Modelled IHME
32 (25 - 39) 2004 Modelled IHME
32 (25 - 39) 2003 Modelled IHME
32 (25 - 39) 2002 Modelled IHME
32 (25 - 39) 2001 Modelled IHME
32 (26 - 39) 2000 Modelled IHME
32 (25 - 39) 1999 Modelled IHME
32 (25 - 39) 1998 Modelled IHME
32 (25 - 38) 1997 Modelled IHME
32 (25 - 38) 1996 Modelled IHME
32 (25 - 38) 1995 Modelled IHME
32 (24 - 38) 1994 Modelled IHME
32 (25 - 39) 1993 Modelled IHME
32 (25 - 39) 1992 Modelled IHME
32 (25 - 39) 1991 Modelled IHME
32 (24 - 39) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
54 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
Yes
OST in at least one prison
Yes

Overview

HBV elimination goal
Year of goal
2030
HCV elimination goal
Year of goal
2030

Prevalence (national)

Modelled

HBV (HBsAg+)
0.36 (%)
2019
(0.31 - 0.4(%))
IHME
HCV (RNA/cAg+)
0.81 (%)
2019
(0.66 - 1(%))
IHME

Survey/surveillance

HBV (HBsAg+)
0.5 (%)
2013
(0.4 - 0.6(%))
WolfframI et al, 2015
HCV (anti-HCV)
0.6 (%)
2002
(0.3 - 1(%))
Huetter ML et al, 2014

Hepatitis related deaths (national)

Modelled

HBV
1,981
2019
(1,509 - 2,606)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
5,748
2019
(4,506 - 7,178)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.02 (%)
2019, latest modelled
(0.01 - 0.02(%))
IHME

Prevalence PWID

HCV
65 (%)
2014, latest modelled
(60.60 - 69.40(%))
Degenhardt L et al, 2017

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Resources